Helix BioPharma Competitors

Helix BioPharma (TSE:HBP) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Helix BioPharma and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

Helix BioPharma has higher earnings, but lower revenue than BELLUS Health. Helix BioPharma is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Helix BioPharma and BELLUS Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Helix BioPharma and BELLUS Health, as provided by MarketBeat.

Summary

BELLUS Health beats Helix BioPharma on 3 of the 4 factors compared between the two stocks.

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Helix BioPharma and Theratechnologies' top-line revenue, earnings per share (EPS) and valuation.

Helix BioPharma has higher earnings, but lower revenue than Theratechnologies. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Helix BioPharma and Theratechnologies, as provided by MarketBeat.com.

Theratechnologies has a consensus price target of C$3.75, indicating a potential downside of 16.67%. Given Theratechnologies' higher probable upside, analysts clearly believe Theratechnologies is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Theratechnologies' net margins, return on equity and return on assets.

Summary

Theratechnologies beats Helix BioPharma on 3 of the 4 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Helix BioPharma has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma, as provided by MarketBeat.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Helix BioPharma's net margins, return on equity and return on assets.

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares ProMetic Life Sciences and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for ProMetic Life Sciences and Helix BioPharma, as provided by MarketBeat.

Profitability

This table compares ProMetic Life Sciences and Helix BioPharma's net margins, return on equity and return on assets.

Summary

ProMetic Life Sciences beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

Neptune Wellness Solutions (TSE:NEPT) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Neptune Wellness Solutions and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Helix BioPharma has lower revenue, but higher earnings than Neptune Wellness Solutions. Helix BioPharma is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Neptune Wellness Solutions and Helix BioPharma, as provided by MarketBeat.

Neptune Wellness Solutions presently has a consensus price target of C$4.63, indicating a potential upside of 214.63%. Given Neptune Wellness Solutions' higher probable upside, analysts plainly believe Neptune Wellness Solutions is more favorable than Helix BioPharma.

Profitability

This table compares Neptune Wellness Solutions and Helix BioPharma's net margins, return on equity and return on assets.

Summary

Neptune Wellness Solutions beats Helix BioPharma on 4 of the 5 factors compared between the two stocks.

Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Helix BioPharma, as provided by MarketBeat.

Profitability

This table compares Medicenna Therapeutics and Helix BioPharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Medicenna Therapeutics and Helix BioPharma's gross revenue, earnings per share (EPS) and valuation.

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.